A Current Review of Targeted Therapeutics for Ovarian Cancer

Abstract EN

Difficult to detect, ovarian cancer typically presents at an advanced stage.

Significant progress has been achieved in the treatment of ovarian cancer with therapeutics focused on DNA replication or cell division.

However, despite sensitivity to induction chemotherapy the majority of patients will develop recurrent disease.

Conventional agents for recurrent disease offer little in terms of long-term responses.

Various targeted therapeutics have been explored in the management of ovarian cancer.

These include monoclonal antibodies to epidermal growth factor receptors, small molecule tyrosine kinase inhibitors, monoclonal antibodies directed at the vascular endothelial growth factor (bevacizumab), and the small tyrosine kinase inhibitors that target the vascular endothelial growth factor receptor.

Recently, several other agents have come forth as potential therapeutic agents in the management of ovarian cancer.

These include monoclonal antibodies to the folate receptor, triple angiokinase inhibitors, PARP inhibitors, aurora kinase inhibitors, inhibitors of the Hedgehog pathway, folate receptor antagonists, and MTOR inhibitors.